CCT-217 Demonstrates Significant Weight Loss and Preserves Lean Body Mass with Potential for Single or Twice-Yearly Dosing
CEO & President, Founder
Chief Strategy Officer, Co-Founder
Senior Scientific Advisor, Gene Therapy and Rare Diseases
Senior Scientific & Medical advisor, Molecular Metabolism
Senior Clinical Development advisor, Obesity & Metabolic Disorder
View DetailsSenior Clinical Development advisor, Obesity & Metabolic Disorder
Senior Scientific Advisor, Obesity & Metabolic Disorders
Legal and Licensing Advisor
Senior Medical Advisor, Neurological Disorders, Parkinson’s Disease
View DetailsSenior Medical Advisor, Neurological Disorders, Parkinson’s Disease
Senior Scientific and Medical advisor , Rare Neurological Disease
Senior Scientific and Medical advisor , Rare Neurological Disease
MD Senior Medical Advisor
CCT-217 Demonstrates Significant Weight Loss and Preserves Lean Body Mass with Potential for Single or Twice-Yearly Dosing New York, November...
First-in-Class Gene-Targeted Approach to Promote Fat-Burning, Preserve Lean Body Mass, and Enhance Metabolic Health by Harnessing the Endocannabinoid System
Canary Global has been accepted into Canada’s SR&ED program which aims to encourage R&D work conducted for the advancement of...